/
As a Delaware corporation formed in February 2025, the Company engages in the business of developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business Combination we were a privately held Puerto Rico corporation incorporated in September 2021.
The business is unprofitable at the operating level (-312016.95% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (FY)
$6K
Net Income (TTM)
-$12M
▼ -1768.9% YoY
Op. Margin
-312016.95%
ROIC
-21197.19%
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$6M
▼ -1756.6% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$6M
Continue Research